This site is intended for healthcare professionals in United Arab Emirates

Search

Menu

Close

Sign InLog Out Our MedicinesTherapy AreasExplore ContentExplore ContentDownloadable materials
VideosLet's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page

Menu

Close

MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines Support & Services Support & Resources Patient support program/tools Events Materials Videos
Ibrance®  US Prescribing Information  Click Here
In an exploratory, long-term pooled analysis, there was no evidence of cumulative or delayed toxicity with up to 50 months of treatment with IBRANCE + letrozole or IBRANCE + fulvestrant in first-line or later treatment1Safety profile remained consistent and manageable with additional follow-up from the Phase III PALOMA-2 and PALOMA-3 trials.2,3Adapted from Diéras V, et al. 2019.1
Data cut-off dates: 2 January 2015 for PALOMA-1, 26 February 2016 for PALOMA-2 and 23 October 2015 for PALOMA-3.1
*Cluster terms were used and are defined in the supplementary materials.
PALOMA-1 = Palbociclib: ongoing trials in the management of breast cancer; PALOMA-2= letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer; PALOMA-3 = the palbociclib ongoing trials in the management of breast cancer 3.

References: 1. Diéras V, et al. J Natl Cancer Inst. 2019;111(4):419-430. 2. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729. 3. Turner NC, et al. N Engl J Med. 2018;379(20):1926-1936.In an analysis of PALOMA-2 and PALOMA-3, IBRANCE + letrozole and IBRANCE + fulvestrant in first-line or later treatment demonstrated a consistent safety profile in patients with visceral disease1Data cut-off dates: 23 October 2015 for PALOMA-3 and 26 February 2016 for PALOMA-2.
*AEs reported using a cluster of PTs as follows: Anaemia is any event having a PT that equals to anaemia or haematocrit decreased or haemoglobin decreased; infections is any event having a PTs that is part of the System Organ Class Infections and infestations; infections is any event having a PT that is part of the System Organ Class Infections and infestations; leukopenia is any event having a PT that equals to leukopenia or white blood cell count decreased; neutropenia is any event having a PT that equals to neutropenia or neutrophil count decreased.
PALOMA-2= letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer; PALOMA-3 = the palbociclib ongoing trials in the management of breast cancer 3; TEAE = treatment-emergent adverse event.

References: 1. Turner NC, et al. Ann Oncol. 2018;29(3):669-680. 2. Turner NC, et al. Ann Oncol. 2018;29(3):669-680. Supplementary Appendix.

Prescribing Information: Master GULF LEVANT-LPD- (Ibrance)- Capsules- 75 mg, 100 mg &125 mg based on USPI Revision date: December 2022 – United Arab Emirates

PP-IBR-ARE-0144

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.

 

ii- The information provided on this website is intended only for healthcare professionals of UAE.
 

PP-UNP-BHR-0180